tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development

Story Highlights
Percheron Therapeutics Advances HMBD-002 Cancer Therapy Development

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Percheron Therapeutics ( (AU:PER) ) has issued an announcement.

Percheron Therapeutics has made significant progress in the development of its lead anti-cancer program, HMBD-002, following the technology transfer from Hummingbird Bioscience. The company has assumed full responsibility for the drug’s development, including regulatory and intellectual property matters, and is preparing for a phase II clinical trial. The recent strengthening of its executive team and consultations with leading scientists and clinicians highlight Percheron’s commitment to advancing HMBD-002’s clinical development. The company plans to share phase I trial results and an overview of the phase II study design with investors, signaling a clear path forward for this promising cancer therapy.

The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases. The company is actively involved in the research and development of innovative cancer treatments, with a particular focus on immunotherapies.

Average Trading Volume: 3,061,336

Technical Sentiment Signal: Sell

Current Market Cap: A$10.87M

Learn more about PER stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1